Sign in
BRNS Stock Price, Chart, Stats & News
Barinthus Biotherapeutics plc
Save
Barinthus Biotherapeutics plc (BRNS) does not currently pay a dividend.
31.00M
Market cap
–
Current P/E
–
Forward P/E
BRNS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.42% |
ROA | -67.67% |
ROE | -70.57% |
D/E | 0.15x |
Interest coverage ratio | -1063.03x |
BRNS valuation
P/E | – |
P/S | – |
P/B | 0.30x |
P/CF | -0.47x |
P/FCF | -0.47x |
P/OCF | -0.47x |
PEG | -0.03x |
EV multiple | -1.39x |
About
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Similar securities
Based on sector and market capitalization
Report issue